Pressure on insulin manufacturers mounts amid US hearings

3 April 2019
insulin_novolog_novo_nordisk

Next week will be the turn of insulin manufacturers to testify about US drug prices in the House of Representatives.

As part of the House’s wider drug pricing probe, executives from Eli Lilly (NYSE: LLY), Novo Nordisk (NOV: N) and Sanofi (Euronext: SAN) will be grilled about the rising cost of the diabetes medicine on Wednesday, April 10.

The House Committee on Energy and Commerce’s Oversight and Investigations Subcommittee is holding a two-part hearing entitled Priced Out of a Lifesaving Drug: The Human Cost of Rising Insulin Prices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight





More Features in Pharmaceutical